Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders (2013 - 2025)
Galmed Pharmaceuticals (GLMD) posted quarterly Net Income towards Common Stockholders of $0.63 for Q2 2025, down 61.82% year-over-year from $1.65 in Q2 2024, and down 61.82% quarter-over-quarter from $1.65 in Q2 2024.
Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at $0.63 for Q2 2025.
- In Q2 2025, Net Income towards Common Stockholders fell 61.82% year-over-year to $0.63; the TTM figure through Mar 2026 stood at $0.63 (down 61.82% YoY), while the FY2025 annual figure was $316000.0, down 16.4% from the prior year.
- Net Income towards Common Stockholders for Q2 2025 stood at $0.63, down from $1.65 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $225000.0 in Q2 2022, with the low at -$106000.0 in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is $1.65 (2024), against an average of $61714.7.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 157.92% in 2022, then jumped 73.68% in 2024.
- Galmed Pharmaceuticals' Net Income towards Common Stockholders stood at $183000.0 in 2021, then slumped by 157.92% to -$106000.0 in 2022, then surged by 100.0% to $0.95 in 2023, then surged by 73.68% to $1.65 in 2024, then plunged by 61.82% to $0.63 in 2025.
- Business Quant data shows GLMD's Net Income towards Common Stockholders at $0.63 in Q2 2025, $1.65 in Q2 2024, and $0.95 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 0.63 |
| Jun 30, 2024 | 1.65 |
| Jun 30, 2023 | 0.95 |
| Sep 30, 2022 | -106,000.00 |
| Jun 30, 2022 | 225,000.00 |
| Sep 30, 2021 | 183,000.00 |
| Mar 31, 2021 | 130,000.00 |
| Dec 31, 2020 | -408.32 Mn |
| Sep 30, 2020 | 408.00 Mn |
| Jun 30, 2020 | -5.24 Mn |
| Mar 31, 2020 | 262,000.00 |
| Dec 31, 2019 | 83.46 Mn |
| Sep 30, 2019 | -11,000.00 |
| Jun 30, 2019 | -16,000.00 |
| Mar 31, 2019 | -36,000.00 |
| Dec 31, 2018 | 3.71 Mn |
| Sep 30, 2018 | 809,000.00 |
| Jun 30, 2018 | -7,000.00 |
| Mar 31, 2018 | 29,000.00 |
| Dec 31, 2017 | 3.64 Mn |